Skip to main content

Clinical trial AMC303-01

A safety, tolerability and pharmacokinetic dose escalation expansion, Phase I/Ib study of AMC303 as monotherapy in patients with advanced or metastatic, malignant solid tumour of epithelial origin

Organ solid tumors
Trial status Trial open for recruitment
Trial type
Prospective interventional
Phase Trial phase 1/1b
Academic trial Non
Sponsor Amcure GmbH
EudraCT Identifier 2016-001358-16
Inclusion criteria any line RECIST 1.1
Last update

Follow us!

Support research

Support research

Research at the Institut Jules Bordet depends on your generosity. Make a donation today and join us in the fight against cancer.

Learn more